An initial higher dose of a peptide given to rapidly reach therapeutic concentration in the body. Often followed by a lower maintenance dose. Common in protocols for BPC-157 blends and growth hormone secretagogues.
"Loading Dose" is filed under Administration in the PeptideAtlas glossary, alongside 15 other terms in that group.
The term applies directly to 1 compound profile here: Degarelix (evidence A). Each profile states the strength of the human evidence rather than only what the compound is claimed to do.
1 other glossary entry refer to this term in their own definition, which is usually the fastest way to see how it is used in practice.
The ongoing dose administered after the loading phase to sustain therapeutic peptide levels. Typically lower than the loading dose and taken over an extended period.
An injection administered into the fatty tissue layer between the skin and muscle. The most common route for peptide self-administration.
An injection administered directly into a muscle. Some peptides may be administered via IM injection under medical supervision.
Administration directly into a vein. Provides 100% bioavailability but requires medical supervision and sterile technique.
Compounds where this applies: Degarelix.
Terms that reference this one: Maintenance Dose.
More Administration terms: Subcutaneous (SubQ), Intramuscular (IM), Intravenous (IV), Intranasal, Sublingual, Topical Peptide, Transdermal, Microneedle Patch, Insulin Syringe, Titration, Maintenance Dose, Peptide Stack, Lipohypertrophy, Injection Site Rotation, Intranasal Delivery.